Disparate patterns of disease time burden in patients with HCC on immunotherapy or tyrosine kinase inhibitors

Background & Aims: While cancer survivorship for hepatocellular carcinoma (HCC) has improved, associated disease time burden in patients taking systemic therapies remains poorly understood. In this study, we used days at home (DAH), a patient-centered metric, to compare the disease time burden b...

Popoln opis

Bibliografske podrobnosti

Principais autores:	Rex Wan-Hin Hui, Matthew Shing-Hin Chung, Lu Li, Xianhua Mao, Chi-Leung Chiang, Carlos King-Ho Wong, Ian Chi-Kei Wong, Ka-Shing Cheung, Man-Fung Yuen, Wai-Kay Seto, Lung-Yi Mak
Format:	Artigo
Jezik:	Inglês
Izdano:	Elsevier 2025-11-01
Serija:	JHEP Reports
Teme:	HCC TKI Immunotherapy irAE
Online dostop:	http://www.sciencedirect.com/science/article/pii/S2589555925002605
Oznake:	Označite Brez oznak, prvi označite!